Other News To Note
Thursday, December 6, 2012
• Vical Inc., of San Diego, said it inked a worldwide, nonexclusive license for rights to its Vaxfectin adjuvant to Cyvax Inc., a privately held vaccine firm, for use in malaria vaccines. Financial terms were not disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.